KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to $24.3 million.

  • CRISPR Therapeutics AG's Other Non-Current Assets rose 11100.69% to $24.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.3 million, marking a year-over-year increase of 11100.69%. This contributed to the annual value of $15.8 million for FY2024, which is 3656.29% up from last year.
  • According to the latest figures from Q3 2025, CRISPR Therapeutics AG's Other Non-Current Assets is $24.3 million, which was up 11100.69% from $25.5 million recorded in Q2 2025.
  • CRISPR Therapeutics AG's 5-year Other Non-Current Assets high stood at $25.5 million for Q2 2025, and its period low was $11.5 million during Q1 2024.
  • Its 5-year average for Other Non-Current Assets is $15.0 million, with a median of $12.1 million in 2022.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Other Non-Current Assets soared by 23414.01% in 2021, and later plummeted by 3291.46% in 2022.
  • CRISPR Therapeutics AG's Other Non-Current Assets (Quarter) stood at $16.9 million in 2021, then tumbled by 31.21% to $11.6 million in 2022, then decreased by 0.38% to $11.6 million in 2023, then soared by 36.56% to $15.8 million in 2024, then soared by 53.57% to $24.3 million in 2025.
  • Its last three reported values are $24.3 million in Q3 2025, $25.5 million for Q2 2025, and $20.8 million during Q1 2025.